

# REEV: review, evaluate and explain variants

Dzmitry Hramyka<sup>1,†</sup>, Henrike Lisa Sczakiel<sup>2,3,4,†</sup>, Max Xiaohang Zhao<sup>1,2,5</sup>, Oliver Stolpe<sup>1</sup>, Mikko Nieminen<sup>1</sup>, Ronja Adam<sup>2,5</sup>, Magdalena Danyel<sup>2,3</sup>, Lara Einicke<sup>2,5</sup>, René Hägerling<sup>1,2,3,4,6</sup>, Alexej Knaus<sup>7</sup>, Stefan Mundlos<sup>2,4</sup>, Sarina Schwartzmann<sup>2</sup>, Dominik Seelow<sup>1,2,5</sup>, Nadja Ehmke<sup>2,5</sup>, Martin Atta Mensah<sup>2,8</sup>, Felix Boschann<sup>2,3,5</sup>, Dieter Beule<sup>1,9,†</sup> and Manuel Holtgrewe<sup>1,\*</sup>

<sup>1</sup>Berlin Institute of Health, Core Unit Bioinformatics, Berlin, Germany

<sup>2</sup>Institute of Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

<sup>3</sup>BIH Biomedical Innovation Academy, Clinician Scientist Program, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

<sup>4</sup>RG Development & Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany

<sup>5</sup>Berlin Institute of Health, Berlin, Germany

<sup>6</sup>Berlin Institute of Health, BIH Center for Regenerative Therapies, Berlin, Germany

<sup>7</sup>Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Germany

<sup>8</sup>BIH Biomedical Innovation Academy, Digital Clinician Scientist Program, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

<sup>9</sup>Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany


\*To whom correspondence should be addressed. Tel: +49 30 450 643607; Fax: +49 30 450 7 543 901; Email: manuel.holtgrewe@bih-charite.de

†The first two and last two authors should be regarded as Joint First and Last Authors.

## Abstract

In the era of high throughput sequencing, special software is required for the clinical evaluation of genetic variants. We developed REEV (Review, Evaluate and Explain Variants), a user-friendly platform for clinicians and researchers in the field of rare disease genetics. Supporting data was aggregated from public data sources. We compared REEV with seven other tools for clinical variant evaluation. REEV (semi-)automatically fills individual ACMG criteria facilitating variant interpretation. REEV can store disease and phenotype data related to a case to use these for phenotype similarity measures. Users can create public permanent links for individual variants that can be saved as browser bookmarks and shared. REEV may help in the fast diagnostic assessment of genetic variants in a clinical as well as in a research context. REEV (<https://reev.bihealth.org/>) is free and open to all users and there is no login requirement.

## Graphical abstract



## Introduction

In recent years, high throughput genetic testing has fundamentally changed the diagnostic paradigm in clinical genetics

(1,2). Hitherto, clinical geneticists were testing a very limited number of genes selected depending on a patient's phenotype. If a variant with severe consequences was found in the patients

Received: February 13, 2024. Revised: April 7, 2024. Editorial Decision: April 23, 2024. Accepted: May 3, 2024

© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

but not in healthy controls, it was likely deemed pathogenic. However, by now access to high throughput genetic analyses such as exome sequencing (ES) or genome sequencing (GS) could be implemented in standard health care (3,4). Accordingly, clinical geneticists have been faced with new challenges. One is, they now have to interpret a considerably larger number of variants from screening assays, hoping to identify the underlying disease-causing mutation among them (5,6). Specialized software is required to achieve this goal. Such tools for variant prioritization usually use two sources of information: variant-specific (molecular, evolutionary and population genetic) features and gene-to-phenotype associations (7–9). However, collecting, connecting and integrating these data about a variant of interest from multiple online sources is time consuming and individual tools frequently lack an easily accessible and comprehensive output (10,11). Also, existing platforms for gathering gene and variant information often fall short by either missing critical data or predictions, or by restricting access to these features to their commercial, full-version offerings (10,12–14). In particular, while several tools exist for the analysis and interpretation of small coding variants, albeit with the limitations mentioned above, there are currently only few platforms for the analysis and evaluation of structural variants (15). Finally, critical to the process of clinical variant evaluation is a robust final assessment of the variant's pathogenicity. To this end, the American College of Medical Genetics and Genomics (ACMG) has developed standardized guidelines for the classification of both sequence and structural variants (16,17). Although there are tools that offer individual or automated ACMG classification, an easy-to-use tool that integrates all these needs in a single platform is lacking.

Here, we introduce such a tool for the analysis, interpretation and ACMG classification of both small and structural variants. REEV (Review, Evaluate and Explain Variants; <https://reev.bihealth.org/>) provides an automated classification proposal, which can be easily understood, adapted, and amended. We also aim to compare REEV with other available web tools for clinical variant evaluation.

## Method outline

All components of the REEV backend pipeline including REEV's specific original code, as well as components using or referring to third-party software and services (Table 1) are free to use in academic and commercial settings (open source, MIT license). All code, tests and data required to run REEV can be found at <https://github.com/bihealth/reev>. A comprehensive user documentation including a quickstart and a tutorial can be found at <https://reev.readthedocs.io/>. REEV is technically designed to speed-up diagnostic variant evaluation and classification in both research and clinical settings. We offer REEV as a complete open-source software suite including comprehensive automated tests as well as deployment scripts following FAIR4RS principles. Thus, REEV can also be individually extended and tailored to the specific needs of the laboratory or clinical institution using it. In several jurisdictions, software used for clinical diagnostics needs to be certified in accordance with national legal regulations. Any laboratory or institution using REEV should be aware that REEV has not been formally certified for diagnostic use in a clinical setting. Responsibility to use REEV or derivatives of REEV in a clinical

setting and certify them for clinical use lies with the using institutions.

## Data storage and preprocessing

On the server, static data is stored in files. Smaller datasets are stored in text files or compressed binary Protocol Buffers format and loaded into memory on startup. To allow for reduced on-disk storage, low main memory footprint and fast lookup, larger datasets are generally stored in RocksDB (an embedded key/value store).

All data is downloaded from public sources using a Snake-make (18,19) workflow (s. also *Data Availability*). The resulting files are publicly available from our S3 server (see also *Data availability*).

## Software architecture and backend

REEV is designed to ensure full transparency and reproducibility of variant analysis in concordance with the FAIR4RS principles (20) and enable timely updates from quickly evolving data sources. REEV is actively maintained with updated releases scheduled once a quarter.

The overall architecture is a typical 'microservice based' web application, as roughly depicted in the graphical abstract. The 'REEV' server is a web server consisting of two layers. The actual user interface consists of a TypeScript/Vue single-page app (SPA) front-end (served through the web server) and a Python/FastAPI based backend for the SPA. The FastAPI server provides functionality for user login and persisting/managing data of logged-in users in a PostgreSQL database. It also functions as a reverse proxy to a number of backend services that provide the actual data and functionality.

These 'microservices' are: *Annonars* provides access to data on genes and variants which are stored in RocksDB databases. *Mehari* provides transcript-based variant consequence annotations (i.e. to project a genomic variant to the transcript-level and compute whether the variant leads to a missense or frameshift variant at protein level). *Viguno* provides access to HPO terms (21–23), a full-text index thereof, and standard ontology algorithms based on information content. The services above are implemented in the Rust programming language. The *cada-prio* service provides phenotype similarity queries based on the CADA (24) algorithm. The *dotty* service provides functionality for transforming variant descriptions between different notation systems, including HGVS (25), using the *hgvs* Python package (26). These two services are implemented in the Python programming language.

These microservices are running (together with utility services such as *nginx*, *traefik*, *PostgreSQL*, *Redis*, and *RabbitMQ*) in Docker containers and orchestrated with Docker Compose.

## Frontend overview

In the following, we focus on the features of the software from the perspective of the user.

REEV allows for the search of genes as well as sequence and structural variants. A short display of supported input styles is shown on the REEV startpage, while a quickstart and full tutorial on how to navigate REEV are provided in the REEV documentation available at <https://reev.readthedocs.io>. Here, we summarize the features implemented in REEV. For a

**Table 1.** Overview of sources and tools integrated with REEV. The REEV backend integrates state-of-the-art databases containing gene and variant related information including condition/disease/phenotype related information, population frequencies, pathogenicity predictions as well as expression and cross species conservation

	Data	Source
Databases	Seqvar frequency	gnomAD (gnomad.broadinstitute.org) (6,30)
	Variant and Gene Scores / Predictions	Variantscores: CADD (57), SpliceAI (58), and many scores from dbNSFP (45), e.g. REVEL (59)
	Gene Information	Gene constraints, e.g. gnomAD pLI/LOEUF/Z-Score (6,30) ClinGen haploinsufficiency and triplosensitivity scores (31) DECIPHER haploinsufficiency and triplosensitivity scores (28)
	Gene-Condition	HGNC ( <a href="https://www.genenames.org/">https://www.genenames.org/</a> ) NCBI Entrez ( <a href="http://www.ncbi.nlm.nih.gov/Entrez/">http://www.ncbi.nlm.nih.gov/Entrez/</a> ) (27) NCBI Gene ( <a href="https://www.ncbi.nlm.nih.gov/gene/">https://www.ncbi.nlm.nih.gov/gene/</a> ) (27)
	Gene Expression	OMIM (26) OrphaData (Orphanet) (32) PanelApp (33) MONDO (60) HPO (21–23)
Internal Services	Clinical databases	GTEX (34) ClinVar (35) ClinGen (31) DECIPHER (28)
	Annonars	<a href="https://github.com/varfish-org/annonars">https://github.com/varfish-org/annonars</a>
	Mehari	<a href="https://github.com/varfish-org/mehari">https://github.com/varfish-org/mehari</a>
	Viguno	<a href="https://github.com/varfish-org/viguno">https://github.com/varfish-org/viguno</a>
	Cada-prio	<a href="https://github.com/varfish-org/cada-prio">https://github.com/varfish-org/cada-prio</a>
Interface with	Dotty	<a href="https://github.com/bihealth/dotty">https://github.com/bihealth/dotty</a>
	ACMG criteria seqvar	InterVar (52)
	ACMG criteria strucvar	AutoCNV (53)
	Phenotype Similarity	CADA (24) and Exomiser (7)
Link-Outs	PubMed	PubTator 3 API (36,37)
	Various	See user manual for further details

REEV frontend allows to interface with semi-automated ACMG scoring tools, phenotype similarity applications and pubmed interfaces. To further support variant evaluation, validation and interpretation REEV also links out to many additional external resources, e.g. to the GA4GH beacon network, VariantValidator or MutationTaster. Current versions of the sources and tools integrated with REEV can be found at <https://reev.cubi.bihealth.org/info#data-versions>.

complete list of integrated sources see Table 1. An overview of the REEV frontend for the query of sequence and structural variants can also be found in [Supplementary Figures S1 and S2](#), respectively.

## Genes

At first, REEV provides basic information about a selected gene, including a short summary from NCBI Gene (27), a list of and link-outs to alternative identifiers for this gene, and link-outs to useful resources on gene level, e.g. DECIPHER (28), OMIM (29), pubmed (27), etc. If applicable for the gene of interest, REEV offers links to locus-specific databases, and NCBI's *References Into Functions (RIFs)*. Next, REEV gives an overview about the gene's potential pathogenicity by providing haploinsufficiency and triplosensitivity scores, e.g. ClinGen (30) DECIPHER (28), gnomAD pLI and pLOEUF (6,30). The user is shown information about associated phenotypes (HPO terms (21–23)) and diseases (OMIM (29), Orphanet (32), Genomics England PanelApp (33)). In the case of a gene with an — as of yet — unknown disease association, REEV also displays gene expression data from the GTEx project (34). Also, REEV offers aggregated ClinVar variant statistics (35). This includes a summary of variant counts, a visualization of variant population frequencies separated by their ACMG class (16), and a plot of the variants' positions and their ACMG classes. Finally, REEV summarizes available information of the gene of interest from the literature providing the ten most relevant hits from PubTator3

(36,37); (full data are available via link-outs to PubTator3 and PubMed).

## Sequence variants

When querying a sequence variant, REEV first provides the above-mentioned details on the respective gene. Following this gene information, the user is presented with a table showing the impact of the variant on different transcripts (according to NCBI GenBank (27,38)). REEV also provides an overview about the variant's ClinVar (35) entries, including whether the variant is present, its respective ClinVar reference assertion, its most pathogenic significance, and its review status. Users can also fold out this ClinVar card and look at the individual reference assertion. Furthermore, in this section REEV provides gnomAD v4 (6) population frequencies of the queried variant in different populations as well as the different sexes (XX vs. XY genotype) and the variant's UCSC 100 vertebrate conservation on protein level (39). Additionally, link-outs to genome browsers (ENSEMBL (40), UCSC (41)) and various external tools (DGV (42), Genoox Franklin (franklin.genoox.com), gnomAD (6,30), MutationTaster (43,44), Varsome (12)) help the user to further assess their variant of interest. REEV not only comes with an integrated display of variant pathogenicity scores from different tools (aggregated by dbNSFP (45)) but also provides a color coded suggestion of the ACMG criterion PP3 as well as raw pathogenicity scores calibrated following Pejaver et al. (46) (see also *ACMG classification*). Finally, users can query the

GA4GH Beacon network (47) for entries of the variant by other institutions. Users may also submit the variant to VariantValidator (48) to obtain gold standard HGVS representation. We provide an example query for the sequence variant chr7:42012159:T:G (i.e. GLI3(NM\_000168.6):c.1880A>C, p.(His627Pro)) using REEV in Figure 2, and online in our REEV tutorial (reev.readthedocs.io).

### Structural variants

Besides sequence variants, REEV also allows users to examine structural variants. These can be provided either in gnomAD (6,30) (GRCh37 or GRCh38 coordinates) or ISCN style (49). As for the sequence variants, REEV first shows general information on the affected gene followed by variant specific information. Here, REEV depicts an overview of the affected genes in the form of a list of genes that are overlapping with or are close to the structural variant. REEV displays how the variant affects every gene (i.e. gene fully or only partially contained; breakpoints exonic, intronic or extragenic). In the case of multiple overlapping genes, users may sort this list of genes by, e.g. gnomAD (6,30) pLI score or the ClinGen (31) haploinsufficiency or triplosensitivity assessment. REEV also depicts details on overlapping variants in ClinVar (35) and the individual reference ClinVar assertions. ClinVar variants will be sorted by reciprocal overlap (the fraction of overlap between the variant studied and the ClinVar variant). Users can see the genomic location of the variant in an integrated IGV genome browser (50) with tracks for interpreting the variant. Users are again provided with link-outs to known external genome browsers (ENSEMBL (40), UCSC (41)) and other external tools (DGV (42), Genoox Franklin (franklin.genoox.com), gnomAD (6,30), Varsome (12)) for further analysis. For an example query in REEV invoking the structural variant DEL:chr14:37131998:37133815, see also Figure 3 as well as the REEV tutorial (reev.readthedocs.io).

### ACMG classification

REEV provides tools for the fast interpretation of sequence and structural variants using the ACMG guidelines for variant interpretation including commonly used modifications. For semi-automated variant classification, REEV considers three rule systems: the original ACMG 2015 guidelines (16), the ACGS 2020 rules (17) and the 2020 point system described by Tavtigian *et al.* (51). REEV offers a short explanation of the definition and application of every of their criteria. For the classification of sequence variants, REEV uses a semi-automated ACMG variant class assessment based on the InterVar (52) tool (Figure 1A, see also below for details). Users can modify and complete this by checking and unchecking every single criterion or altering its level of evidence (supporting, moderate, strong, or very strong), clear all criteria or reset to auto-fill (Figure 1A, B). Users can customize the application of the PP3-criterion (e.g. adapt the level of evidence according to the applied pathogenicity prediction tool) (Figure 1C). Semi-automated classification of structural variants is performed following ACMG and ClinGen standards (17) using the AutoCNV (53) tool (see below for details). As for sequence variants, users can modify each criterion by checking and unchecking or adapting the points given for the respective criterion (Figure 1D). Since both, InterVar and AutoCNV, can provide inaccurate pathogenicity predictions not only manual completion of unassigned ACMG criteria but also checking of

prefilled ACMG criteria is crucial for the correct assessment of a variant. Therefore, we designed REEV as a diagnostic decision support system putting a focus on the semi-automated classification by the user themselves. To this end, REEV assists the user with the aforementioned explanation of the definition and application of every ACMG criterion and the easy option to adapt them.

### Automated ACMG classification by InterVar and AutoCNV

InterVar (52) implements an automated evaluation of the ACMG criteria (16) including the pathogenic PVS1, PS1, PS4, PM1, PM2, PM4, PM5, PP2, PP3, PP5 criteria and the benign BA1, BS1, BS2, BP1, BP3, BP4, BP6, BP7 criteria. InterVar uses ESP6500, 1000 Genomes and ExAC for evaluating population frequency data. Prediction scores are obtained through dbNSFP and dbSCNV, with MetaSVM used as a score for deleteriousness and GERP++ used for conservation. Splice predictions use ADA and RF scores. Pathogenicity information is determined through ClinVar variants.

AutoCNV (53) automatically classifies CNVs using the ACMG/ClinGen CNV criteria (17). AutoCNV implements automated evaluation of all criteria in Section 1 and 3, as well as most of Section 2 (excluding 2J and 2K) and criteria 4O in Section 4. DGV (42) and gnomAD (6,30) were used to obtain frequency information. Haploinsufficiency and triplosensitivity information were obtained through Decipher (28). AutoPVS1 (54) is used to evaluate the impact of gene-level duplications and deletions. All sections and criteria concerned with phenotype specificity, segregation or patient phenotyping require manual evaluation by the user.

### Additional features for logged-in users

While REEV is fully functional without login, there are a few features only available after login. Storing ACMG assessment and bookmarks on the server requires a login to be uniquely assigned to users and across computers. Users can always store the persistent URLs into the REEV server as browser bookmarks and share these URLs without registration, e.g. via Email. ClinVar (35) uploads can only be made available after login as this requires depositing the institution's ClinVar API key on the server which should be protected by login.

Logging in is possible via an ORCID account (55) or Life-Science RI (56) (which allows researchers in the European Union to use their home institution accounts).

### Storing bookmarks and ACMG assessments

Logged-in users can store bookmarks on genes and variants on the server. In addition, they can store the phenotype information they entered for their case as well as the ACMG variant assessment scores (both the automated analysis results as well as their adjustments).

### ClinVar upload

Logged-in users can deposit their ClinVar (35) API key and use it to submit their clinical variant assessments to ClinVar. To the best of our knowledge, REEV is the first graphical tool to allow for such uploads via the API. Submission via the API has the advantage that ClinVar submission accession identifiers can be obtained within a few hours.

We plan to add further functionality for logged-in users such as publicly sharing comments on variants.



**Figure 1.** Semi-automated ACMG Classification. Overview of semi-automated variant classification using REEV. (A–C) ACMG classification of a sequence variant. (A) Semi-automated classification based on the InterVar tool. The user can (de)activate a terse mode (1), show or hide failed ACMG criteria (2) and clear or reset chosen criteria to auto (3) meaning they are computed rather than user set. Logged in users can also load and save the classification of variants (4). Every criterion can be (de)selected manually (5) and set at the chosen level of confidence (6). (B) Example of this manual setting of the level of confidence for the variable pathogenicity prediction criterion PP3. (C) Overview of variant pathogenicity scores from different tools (aggregated by dbNSFP) as well as color coding and calibrated scores where applicable for an easy and correct usage of the modified PP3 criterion following Pejaver *et al.* (46). (D) Semi-automated ACMG classification of a structural variant based on AutoCNV (applicable for ACMG/ClinGen CNV criteria 1–3 of 5 (17)), which can also be reset (7), (de)selected manually (8) and set at the chosen level of confidence (9).

Table 2. Feature comparison of REEV with existing tools

Tool	URL	Latest update	Documentation / Tutorial	Support of structural variants	Gene info	Gene pathogenicity	Associated conditions	Gene literature	Direct literature link-outs	Gene expression	Gene ClinVar	Case specificity / Gene-to-phenotype ranking	Variant pathogenicity scores	Variant tool link-outs	Variant classification (according ACMG guidelines)	Integrated genome browser	Integrated protein viewer	Pharmacology information	Customization options	Option for ClinVar upload	Login required?	additional features with login?	Open access?	Open source?	Certified for clinical use?	academic or commercial?
REEV	reev.bihealth.org	2024	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
AutoCNV	phoenix.bgi.com/autocnv/	2021	-	✓	-	-	-	-	-	-	-	-	-	-	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
DECIPHER	deciphergenomics.org	2024	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
Ensembl VEP Web	ensembl.org/Tools/VEP	2024	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
GeneBe	genebe.net	2023	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
Genoox Franklin	franklin-genoox.com	2023	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	commercial	
InterVar	wintervar.wglab.org	2022	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
UCSC Variant	genome.ucsc.edu/cgi-bin/hgVai	2024	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
Annotation Integrator	mulinlab.org/vportal	2020	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
VannoPortal	genemed.tech/varcards	2019	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
VarCards	genemed.tech/varcards	2019	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	academic	
Varsome	varsome.com	2024	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	commercial	

<sup>1</sup>limited functionality; <sup>2</sup>limited access without login; <sup>3</sup>limited access without purchase; <sup>4</sup>linkout only; <sup>5</sup>pubmed link-out only; <sup>6</sup>ClinVar only; <sup>7</sup>UCSC only; <sup>8</sup>GWAS only; <sup>9</sup>access only upon purchase; <sup>10</sup>for structural variants only.

## Benchmarking and software testing

We benchmarked REEV's performance with regard to accuracy and speed using a defined set of 10 different variants investigated independently by six different clinicians. These ten variants comprise two null variants, two missense variants, two splice site variants, two deletions and two duplications (Supplementary Table S1). Correctness of displayed information (e.g. gnomAD frequencies, ClinVar entries, pathogenicity predictions, etc.) was checked. Classification of variants was carried out according to current ACMG and ACGS guidelines (16,17,51). Time until reaching final ACMG classification was measured and compared between using REEV and single look-up of information required for classification. Statistical analysis was performed using a one-sided paired *t*-test.

## Results and discussion

Here we present REEV, a free and open tool for the user-friendly automated clinical evaluation of genetic variants.

### Accuracy and performance in comparison to single tools

Testing REEV's accuracy using ten different benchmarking variants showed a correct presentation of this information. When this information was used to classify the respective variant with the help of the semi-automated ACMG classification offered by REEV this classification overall matched the clinician's classification reached without using REEV. For small variants, REEV significantly reduced the time required to reach final ACMG classification (compared to single look-up of information). For structural variants we could only detect a significant reduction of the time required for classification for deletions (Supplementary Figure S3).

### Comparison to existing integrative tools

To benchmark REEV's potential use in the clinical routine, we compared REEV and ten similar state-of-the-art web tools (Table 2). Of the ten evaluated tools gathering variant effect prediction, only five provide (detailed) information on gene-disease-associations. The only other tool enabling the annotation with case specific phenotype information and returning gene-to-phenotype ranks is the commercial platform Genoox Franklin. A frequent short-coming of existing variant interpretation platforms is their restriction to coding small variants. Apart from REEV, we found only DECIPHER and the two merely commercial services, Genoox Franklin and Varsome, supporting both small variants and structural variants. The ability to submit variants directly to the ClinVar database is only available in one other software: the commercial offering Varsome.

### Distinctive features and use cases

With REEV we present a free and open easy-to-use, versatile web application that integrates all relevant information on genes, sequence, and structural variants into one single platform. By combining extensive information on genes and their clinical relevance (gene-disease associations, dosage sensitivity scores, etc.) as well as compiling variant specific pathogenicity predictions and database information (gnomAD v4, ClinVar, etc.) REEV sets the basis for the rapid and thorough

**A Case Information**

You can store information about your current case here. The HPO terms will be used to prioritize genes using the CADA algorithm. On the right, you will see all known disease genes ranked by their CADA score. Also, you will see the rank in the details section of each gene.

Pseudonym **1**

SeqVar

HPO Terms

Preaxial hand polydactyly (HP:0001177) Macrocephaly (HP:000256) **2**

Preaxial foot polydactyly (HP:0001841) Postaxial foot polydactyly (HP:0001830)

Finger syndactyly (HP:0006101) Toe syndactyly (HP:0001770)

Start typing to search for OMIM diseases

SAVE CHANGES DELETE CASE INFO

**3** CADA-prio gene ranking for current HPO:

#	Gene Symbol	Score
1	LMBR1	87.83
2	HOXD13	84.07
3	BHLHA9	75.59
4	GLI3	69.86
5	DYNC2H1	64.58
6	WNT7A	63.89
7	DDX59	60.59
8	GRIP1	59.09

**B Consequences**

VARIANT CONSEQUENCES ON OVERLAPPING TRANSCRIPTS

Gene	Transcript	Consequence	HGVS.p	HGVS.t	Exon/Intron
GLI3	NM_000168.6 (Coding) MANE Select	missense_variant	c.1880A>C	p.H627P	13 / 15

**C Associated Conditions**

PHENOTYPES AND DISORDERS ASSOCIATED WITH GENE

Associated Diseases (3 of 8) • show all

sort by name **4** ASC

ACROCCALLOSAL SYNDROME

Description: A rare polymalformative syndrome characterized by agenesis of corpus callosum (CC), distal anomalies of limbs, minor craniofacial anomalies and intellectual disability.

Confidence: ★★★ • Sources: Orphanet

Additional Information +

GENE-TO-PHENOTYPE RANK **5**

#4

out of 5 130 genes

CADA score: 69.86

**D Clinical Significance**

SEMI-AUTOMATED PATHOGENICITY PREDICTION

Classification of variants is based on InterVar (Li & Wang, 2017) which follows the ACMG 2015 criteria (Richards et al., 2015).

InterVar provides prediction

HIDE TERSE MODE

SHOW FAILED CRITERIA

SEMI-AUTOMATED ACMG PATHOGENICITY PREDICTION

Uncertain significance

CLEAR RESET TO INTERVAR DOCUMENTATION

SAVE TO SERVER

LOAD FROM SERVER

DELETE FROM SERVER

PATHOGENIC

PM1 PM2 PP3

Pathogen... Pathogen... Pathogen...

BENIGN

BP1

Benign S...

**E Clinical Significance**

SEMI-AUTOMATED PATHOGENICITY PREDICTION

Classification of variants is based on InterVar (Li & Wang, 2017) which follows the ACMG 2015 criteria (Richards et al., 2015).

InterVar provides prediction

HIDE TERSE MODE

SHOW FAILED CRITERIA

SEMI-AUTOMATED ACMG PATHOGENICITY PREDICTION

Likely pathogenic

CLEAR RESET TO INTERVAR DOCUMENTATION

SAVE TO SERVER

LOAD FROM SERVER

DELETE FROM SERVER

PATHOGENIC

PS4 PM1 PM2 PP3

Pathogen... Pathogen... Pathogen... Pathogen...

BENIGN

BP1

Benign S...

ClinVar

Significance likely pathogenic

Review Status ★☆☆☆ criteria provided, single submitter

Accession VCV001120242

SHOW REFERENCE ASSERTIONS

**Figure 2.** Use case: sequence variant. Example query for the sequence variant chr7:42012159:T:G. Variants can be either entered as genomic variant or on cDNA level providing the corresponding GenBank transcript variant, e.g. NM\_000168.6(*GLI3*):c.1880A>C. Here, we highlight key features provided by REEV; for a full use case demonstration, e.g. including an example on the overview given to the affected gene, see the REEV quickstart and tutorial at reev.readthedocs.io. **(A)** Logged-in users can provide a case specific pseudonym/id **(1)** and phenotype information in the form of HPO terms or OMIM diseases **(2)**. In our example, we provided a patient phenotype which is a preaxial hand and foot polydactyly, foot postaxial polydactyly, syndactyly and macrocephaly. REEV automatically suggests possible genes linked to the given phenotype, as well as genes, variants in which might be likely to be causative of this phenotype (as provided by CADA-prio HPO-gene-ranking) (note, that this phenotypic information does not influence automated variant predictions by InterVar and AutoCNV, but the results of these gene-to-phenotype rankings can be taken into account by the user for the manual completion of variant classification according to ACMG guidelines.) **(3)** *GLI3*, the gene affected by the likely causative variant, is listed in 4th position and possible differential diagnoses: *LMBR1*, *HOXD13*, etc. are also shown. **(B)** Overview of the variant and its consequences summarized by REEV. **(C)** Associated conditions (shown here: Orphanet; but OMIM, HPO and Genomics England PanelApp are also available in REEV) for the gene affected by the respective variant. This list can also be sorted either by name or level of confidence **(4)**. Note, when logged-in users have provided case specific phenotype information (see A), here they are shown a gene-to-phenotype rank (according to CADA ranking) **(5)**. **(D)** Semi-automated ACMG classification based on InterVar which classifies this variant as of uncertain significance. **(E)** Manual input of further information allows for the final classification as likely pathogenic: REEV shows that this variant is listed once in the ClinVar database as likely pathogenic (\*). We thus can additionally assign the ACMG criterion PS4 on supporting level. Using REVEL as our reference pathogenicity prediction tool and this variant yielding a REVEL score of 0.96 we can use the PP3 criterion at strong level according to Pejaver *et al.* (46) (see also Figure 1A–C).

**A Case Information**

You can store information about your current case here. The HPO terms will be used to prioritize genes using the CADA algorithm. On the right, you will see all known disease genes ranked by their CADA score. Also, you will see the rank in the details section of each gene.

Pseudonym  
StrucVar

HPO Terms  
Oligodontia (HP:0000677)

Start typing to search for OMIM diseases

SAVE CHANGES DELETE CASE INFO

**B Gene List**  
OVERLAPPING AND CONTAINED GENES

sort by symbol ASC  $\updownarrow$

#	Gene Symbol	Score
1	PAX9	101.92
2	LRP6	91.95
3	AXIN2	88.35
4	EDA	87.23
5	MSX1	86.18
6	WNT10A	83.89
7	EDARADD	83.52

**C Associated Conditions**  
PHENOTYPES AND DISORDERS ASSOCIATED WITH GENE

Associated Diseases (1) sort by name ASC  $\updownarrow$

**NON RARE IN EUROPE: Hypodontia**  
Description: Oligodontia is a rare developmental dental anomaly in humans characterized by the absence of six or more teeth.  
Confidence: ★★ ★ Sources: OMIM, Orphanet, PanelApp  
Additional Information +

**D Clinical Significance**  
SEMI-AUTOMATED PATHOGENICITY PREDICTION  
Classification of CNVs is based on AutoCNV (Fan et al., 2021) which follows the ACMG 2020 criteria (Riggs et al., 2020).

SEMI-AUTOMATED ACMG PATHOGENICITY PREDICTION  
**Uncertain significance with score: 0.45**  
RESET TO AUTO DOCUMENTATION

Evidence	Description	Suggested points	Max score
L1A	Copy number loss content Contains protein-coding or other known functionally important elements.	0	0
L2E	See ClinGen SVI working group PVS1 specifications • PVS1 = 0.90 (Range: 0.45 to 0.90) • PVS1_Strong = 0.45 (Range: 0.30 to 0.90) • PVS1_Moderate or PM4 (in-frame indels) = 0.30 (Range: 0.15 to 0.45) • PVS1_Supporting = 0.15 (Range: 0 to 0.30) • N/A = No points, but continue evaluation Both breakpoints are within the same gene (intragenic CNV, gene-level sequence variant). See ClinGen SVI working group PVS1 specifications • PVS1 = 0.90 (Range: 0.45 to 0.90) • PVS1_Strong = 0.45 (Range: 0.30 to 0.90) • PVS1_Moderate or PM4 (in-frame indels) = 0.30 (Range: 0.15 to 0.45) • PVS1_Supporting = 0.15 (Range: 0 to 0.30) • N/A = No points, but continue evaluation.	0	0.9
L3A	Number of protein-coding RefSeq genes wholly or partially included in the copy-number loss 0-24 genes.	0	0
L4E	Individual case evidence — unknown inheritance (range: 0 to 0.15) Reported proband has a highly specific phenotype consistent with the gene/genomic region, but the inheritance of the variant is unknown.	0.1	0.3
L5A	Observed copy-number loss is de novo. Use de novo scoring categories from section 4 (4A-4D) to determine score Use appropriate category from de novo scoring section in section 4.	0	0.45

**E**

SEMI-AUTOMATED ACMG PATHOGENICITY PREDICTION  
**Pathogenic with score: 1.2**  
RESET TO AUTO DOCUMENTATION

**Figure 3.** Use case: structural variant. Example query of the structural variant DEL:chr14:37131998:37133815. Again, here we demonstrate the unique features provided by REEV; for a full use case demonstration see the REEV quickstart and tutorial at reev.readthedocs.io. **(A)** Logged-in users can provide case specific phenotype information (here we provided our patient's phenotype which is oligodontia). Again, REEV suggests possible genes linked to the given phenotype (as provided by CADA-prio HPO-gene-ranking) (PAX9, the gene affected by our variant is listed 1st). **(B)** Full list of genes affected by our variant as well as different dosage sensitivity scores (provided by ClinGen, gnomAD, RCNV) of the respective gene. This list can also be sorted either by gene symbol or score of interest. **(C)** Associated conditions for the gene affected by the respective variant. This list can be sorted either by name or level of confidence. Again, when a logged-in user has provided case specific phenotype information (see A), they are shown a gene-to-phenotype rank (according to CADA ranking), in our example rank for a variant in PAX9. **(D)** Semi-automated ACMG classification of our structural variant based on AutoCNV (see also Figure 1D) yields a variant of uncertain significance with the CNV criteria L1A true (deletion contains part of a protein coding gene), L2E true with 0.45 points (corresponding to the PVS1 criterion; our variant abrogates >10% of the protein and PVS1 is to be used at strong level, equaling 0.45 points for L2E) and L3A true (for number of contained genes is 0–24). **(E)** Manual input of further information allows for the final classification as pathogenic: ClinVar information of this variant provided by REEV revealed several (likely) pathogenic loss of function sequence variants in PAX9, therefore criterion L4E is true with 0.3 points. Also, we identified this variant in a trio-genome sequencing as a *de novo* variant, so criterion L5A is true with 0.45 points.



evaluation of a variant of interest. As described above, a stand-alone feature of REEV amongst further academic variant interpretation platforms is its capability of taking case specific phenotype information and returning gene-to-phenotype ranking, helping the user to rate a variant's significance. To achieve this, we implemented semi-automated predictions for small (InterVar) and structural (AutoCNV) variants and combined them with a flexible, easy-to-use interactive system for manual interpretation and completion of ACMG criteria (Figure 1). However, REEV does not only aim to support the daily work of assessing a variant's relevance in routine NGS diagnostics but also wants to provide valuable additional information when it comes to rating a variant's possible significance in a research setting. We summarize and demonstrate these features in two use cases, one for a sequence (Figure 2) and one for a structural variant (Figure 3).

## Conclusion

REEV is a free versatile web tool that implements all the information needed for a fast and complete assessment of sequence as well as structural variants. By allowing for case specific phenotype-to-gene ranking, REEV assists the user in a fast prioritization of clinically relevant variants. With a special focus on ACMG classification and an user-friendly way of submitting the evaluated variant to the ClinVar database, REEV is useful in a clinical geneticist's daily routine. REEV also provides valuable additional information necessary when further evaluating variants in a research context.

REEV is used in the authors' daily work and actively maintained. We welcome questions, comments, and suggestions via email or the GitHub project's issue tracker and discussion forum.

## Data availability

All data is available for download as described in the software manual attached as Supplementary Data, in particular software available on GitHub under permissive MIT license and also deposited with Zenodo (<https://doi.org/10.5281/zenodo.10424214>). This also includes all pipelines and software to download and preprocess the data as well as test code and deployment scripts. All data has been aggregated and generated from freely available sources. Instructions for downloading the data from our S3 server are available in the software manual as well.

## Supplementary data

Supplementary Data are available at NAR Online.

## Acknowledgements

The authors thank all users for the reporting of bugs and suggestions of enhancements.

Emojis by OpenMojito – the open-source emoji and icon project, license: CC BY-SA 4.0.

## Funding

H.L.S., M.D. and R.H. are participants in the BIH Charité Clinician Scientist Program and M.A.M. in the BIH Char-

ité Digital Clinician Scientist Program, both founded by the late Prof. Duska Dragun and funded by the Charité—Universitätsmedizin Berlin and the Berlin Institute of Health. F.B. is a participant in the Clinician Scientist Program (CS4RARE) funded by the Alliance4Rare and associated with the above mentioned BIH Charité Clinician Scientist Program. D.B. received funding from the German national omics data infrastructure NFDI-GHGA, grant number 441914366, NFDI1/1. Funding for open access charge: Institute funds and/or funds through the Charite University Medicine Library.

## Conflict of interest statement

None declared.

## References

- Sun, Y., Ruivenkamp, C.A.L., Hoffer, M.J.V., Vrijenhoek, T., Kriek, M., Asperen, C.J., Dunnen, J.T. and Santen, W.E. (2015) Next-generation diagnostics: gene panel, exome, or whole genome? *Hum. Mutat.*, **36**, 648–655.
- Kliegman, R.M. and Bordini, B.J. (2020) In: *Undiagnosed and Rare Diseases, An Issue of Clinics in Perinatology: Undiagnosed and Rare Diseases, An Issue of Clinics in Perinatology*. Elsevier Health Sciences.
- Turro, E., Astle, W.J., Megy, K., Gräf, S., Greene, D., Shamardina, O., Allen, H.L., Sanchis-Juan, A., Frontini, M., Thys, C., et al. (2020) Whole-genome sequencing of patients with rare diseases in a national health system. *Nature*, **583**, 96–102.
- Schmidt, A., Danyel, M., Grundmann, K., Brunet, T., Klinkhammer, H., Hsieh, T.-C., Engels, H., Peters, S., Knaus, A., Moosa, S., et al. (2023) Next-generation phenotyping integrated in a national framework for patients with ultra-rare disorders improves genetic diagnostics and yields new molecular findings. medRxiv doi: <https://doi.org/10.1101/2023.04.19.23288824>, 25 April 2023, preprint: not peer reviewed.
- Lappalainen, T., Scott, A.J., Brandt, M. and Hall, M. (2019) Genomic analysis in the age of human genome sequencing. *Cell*, **177**, 70–84.
- Chen, S., Francioli, L.C., Goodrich, J.K., Collins, R.L., Kanai, M., Wang, Q., Alföldi, J., Watts, N.A., Vittal, C., Gauthier, L.D., et al. (2023) A genomic mutational constraint map using variation in 76,156 human genomes. *Nature*, **625**, 92–100.
- Smedley, D., Jacobsen, J.O.B., Jäger, M., Köhler, S., Holtgrewe, M., Schubach, M., Siragusa, E., Zemojtel, T., Buske, O.J., Washington, N.L., et al. (2015) Next-generation diagnostics and disease-gene discovery with the exomiser. *Nat. Protoc.*, **10**, 2004–2015.
- Holtgrewe, M., Stolpe, O., Nieminen, M., Mundlos, S., Knaus, A., Kornak, U., Seelow, D., Segebrecht, L., Spielmann, M., Fischer-Zirnsak, B., et al. (2020) VarFish: comprehensive DNA variant analysis for diagnostics and research. *Nucleic Acids Res.*, **48**, W162–W169.
- Hombach, D., Schuelke, M., Knierim, E., Ehmke, N., Schwarz, J.M., Fischer-Zirnsak, B. and Seelow, D. (2019) MutationDistiller: user-driven identification of pathogenic DNA variants. *Nucleic Acids Res.*, **47**, W114–W120.
- Xin, J., Mark, A., Afrasiabi, C., Tsung, G., Juchler, M., Gopal, N., Stupp, G.S., Putman, T.E., Ainscough, B.J., Griffith, O.L., et al. (2016) High-performance web services for querying gene and variant annotation. *Genome Biol.*, **17**, 91.
- Niroula, A. and Vihinen, M. (2016) Variation interpretation predictors: principles, types, performance, and choice. *Hum. Mutat.*, **37**, 579–597.
- Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C.E., Aguilera, M.A., Meyer, R. and Massouras, A. (2018) VarSome: the human genomic variant search engine. *Bioinformatics*, **35**, 1978–1980.

13. Li,J., Shi,L., Zhang,K., Zhang,Y., Hu,S., Zhao,T., Teng,H., Li,X., Jiang,Y., Ji,L., *et al.* (2018) VarCards: an integrated genetic and clinical database for coding variants in the human genome. *Nucleic Acids Res.*, **46**, D1039–D1048.
14. Huang,D., Zhou,Y., Yi,X., Fan,X., Wang,J., Yao,H., Sham,P.C., Hao,J., Chen,K. and Li,J. (2022) VannoPortal: multiscale functional annotation of human genetic variants for interrogating molecular mechanism of traits and diseases. *Nucleic Acids Res.*, **50**, D1408–D1416.
15. Geoffroy,V., Lamouche,J.-B., Guignard,T., Nicaise,S., Kress,A., Scheidecker,S., Béchéac,A.L. and Muller,J. (2023) The AnnotSV webserver in 2023: updated visualization and ranking. *Nucleic Acids Res.*, **51**, W39–W45.
16. Richards,S., Aziz,N., Bale,S., Bick,D., Das,S., Gastier-Foster,J., Grody,W.W., Hegde,M., Lyon,E. and Spector,E. (2015) Karl Voelkerding, Heidi L Rehm, and ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. *Genet. Med.*, **17**, 405–424.
17. Rooney Riggs,E., Andersen,E.F., Cherry,A.M., Kantarci,S., Kearney,H., Patel,A., Raca,G., Ritter,D.I., South,S.T., Thorland,E.C., *et al.* (2020) Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the american college of medical genetics and genomics (ACMG) and the clinical genome resource (ClinGen). *Genet. Med.*, **22**, 245–257.
18. Mölder,F., Jablonski,K.P., Letcher,B., Hall,M.B., Tinch,C.H.T., Sochat,V., Forster,J., Lee,S., Twardziok,S.O., Kanitz,A., *et al.* (2021) Sustainable data analysis with snakemake. *F1000Res*, **10**, 33.
19. Köster,J. and Rahmann,S. (2012) Snakemake—a scalable bioinformatics workflow engine. *Bioinformatics*, **28**, 2520–2522.
20. Barker,M., Hong,N.P.C., Katz,D.S., Lamprecht,A.-L., Ortiz,C.M., Psomopoulos,F., Harrow,J., Castro,L.J., Gruenpeter,M., Martinez,P.A., *et al.* (2022) Introducing the FAIR principles for research software. *Sci. Data*, **9**, 622.
21. Robinson,P.N., Köhler,S., Bauer,S., Seelow,D., Horn,D. and Mundlos,S. (2008) The human phenotype ontology: a tool for annotating and analyzing human hereditary disease. *Am. J. Hum. Genet.*, **83**, 610–615.
22. Köhler,S., Gargano,M., Matentzoglou,N., Carmody,L.C., Smith,D.L., Vasilevsky,N.A., Danis,D., Balagura,G., Baynam,G., Brower,A.M., *et al.* (2021) The human phenotype ontology in 2021. *Nucleic Acids Res.*, **49**, D1207–D1217.
23. Gargano,M.A., Matentzoglou,N., Coleman,B., Addo-Lartey,E.B., Anagnostopoulos,A.V., Anderton,J., Avillach,P., Bagley,A.M., Bakstein,E., Balhoff,J.P., *et al.* (2024) The human phenotype ontology in 2024: phenotypes around the world. *Nucleic Acids Res.*, **52**, D1333–D1346.
24. Peng,C., Dieck,S., Schmid,A., Ahmad,A., Knaus,A., Wenzel,M., Mehner,L., Zirn,B., Haack,T., Ossowski,S., *et al.* (2021) CADA: phenotype-driven gene prioritization based on a case-enriched knowledge graph. *NAR Genom. Bioinform.*, **3**, lqab078.
25. Dunnen,J.T. (2017) Describing sequence variants using HGVS nomenclature. *Methods Mol. Biol.*, **1492**, 243–251.
26. Hart,R.K., Rico,R., Hare,E., Garcia,J., Westbrook,J. and Fusaro,A. (2015) A python package for parsing, validating, mapping and formatting sequence variants using HGVS nomenclature. *Bioinformatics*, **31**, 268–270.
27. Sayers,E.W., Bolton,E.E., Rodney Brister,J., Canese,K., Chan,J., Comeau,D.C., Connor,R., Funk,K., Kelly,C., Kim,S., *et al.* (2022) Database resources of the national center for biotechnology information. *Nucleic Acids Res.*, **50**, D20–D26.
28. Firth,H.V., Richards,S.M., Paul Bevan,A., Clayton,S., Corpas,M., Rajan,D., Vooren,S.V., Moreau,Y., Pettett,R.M. and Carter,P. (2009) DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. *Am. J. Hum. Genet.*, **84**, 524–533.
29. McKusick,V.A. (2007) Mendelian inheritance in man and its online version, OMIM. *Am. J. Hum. Genet.*, **80**, 588–604.
30. Karczewski,K.J., Francioli,L.C., Tiao,G., Cummings,B.B., Alföldi,J., Wang,Q., Collins,R.L., Laricchia,K.M., Ganna,A., Birnbaum,D.P., *et al.* (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*, **581**, 434–443.
31. Rehm,H.L., Berg,J.S., Brooks,L.D., Bustamante,C.D., Evans,J.P., Landrum,M.J., Ledbetter,D.H., Maglott,D.R., Martin,C.L., Nussbaum,R.L., *et al.* (2015) ClinGen. ClinGen—the clinical genome resource. *N. Engl. J. Med.*, **372**, 2235–2242.
32. Rath,A., Olry,A., Dhombres,F., Brandt,M.M., Urbero,B. and Ayme,S. (2012) Representation of rare diseases in health information systems: the orphanet approach to serve a wide range of end users. *Hum. Mutat.*, **33**, 803–808.
33. Martin,A.R., Williams,E., Foulger,R.E., Leigh,S., Daugherty,L.C., Niblock,O., Leong,I.U.S., Smith,K.R., Gerasimenko,O., Haraldsdottir,E., *et al.* (2019) PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat. Genet.*, **51**, 1560–1565.
34. Consortium,G.T.E. (2020) The GTEx consortium atlas of genetic regulatory effects across human tissues. *Science*, **369**, 1318–1330.
35. Landrum,M.J., Chitipiralla,S., Brown,G.R., Chen,C., Gu,B., Hart,J., Hoffman,D., Jang,W., Kaur,K., Liu,C., *et al.* (2020) ClinVar: improvements to accessing data. *Nucleic Acids Res.*, **48**, D835–D844.
36. Wei,C.-H., Allot,A., Lai,P.-T., Leaman,R., Tian,S., Luo,L., Jin,Q., Wang,Z., Chen,Q. and Lu,Z. (2024) PubTator 3.0: an AI-powered literature resource for unlocking biomedical knowledge. *Nucleic Acids Res.*, <https://doi.org/10.1093/nar/gkac235>.
37. Wei,C.-H., Allot,A., Leaman,R. and Lu,Z. (2019) PubTator central: automated concept annotation for biomedical full text articles. *Nucleic Acids Res.*, **47**, W587–W593.
38. Benson,D.A., Cavanaugh,M., Clark,K., Karsch-Mizrachi,I., Lipman,D.J., Ostell,J. and Sayers,E.W. (2013) GenBank. *Nucleic Acids Res.*, **41**, D36–D42.
39. Miller,W., Rosenbloom,K., Hardison,R.C., Hou,M., Taylor,J., Raney,B., Burhans,R., King,D.C., Baertsch,R., Blankenberg,D., *et al.* (2007) 28-way vertebrate alignment and conservation track in the UCSC genome browser. *Genome Res.*, **17**, 1797–1808.
40. Howe,K.L., Achuthan,P., Allen,J., Allen,J., Alvarez-Jarreta,J., Amode,M.R., Armean,I.M., Azov,A.G., Bennett,R., Bhai,J., *et al.* (2021) Ensembl 2021. *Nucleic Acids Res.*, **49**, D884–D891.
41. James Kent,W., Sugnet,C.W., Furey,T.S., Roskin,K.M., Pringle,T.H., Zahler,A.M. and Haussler,D. (June 2002) The human genome browser at UCSC. *Genome Res.*, **12**, 996–1006.
42. MacDonald,J.R., Ziman,R., Yuen,R.K.C., Feuk,L. and Scherer,W. (2014) The database of genomic variants: a curated collection of structural variation in the human genome. *Nucleic Acids Res.*, **42**, D986–D992.
43. Schwarz,J.M., Rödelberger,C., Schuelke,M. and Seelow,D. (2010) MutationTaster evaluates disease-causing potential of sequence alterations. *Nat. Methods*, **7**, 575–576.
44. Steinhaus,R., Proft,S., Schuelke,M., Cooper,D.N., Schwarz,J.M. and Seelow,D. (2021) MutationTaster2021. *Nucleic Acids Res.*, **49**, W446–W451.
45. Liu,X., Li,C., Mou,C., Dong,Y. and Tu,Y. (2020) dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. *Genome Med.*, **12**, 103.
46. Pejaver,V., Byrne,A.B., Feng,B.-J., Pagel,K.A., Mooney,S.D., Karchin,R., O'Donnell-Luria,A., Harrison,S.M., Tavtigian,S.V., Greenblatt,M.S., *et al.* (2022) and ClinGen Sequence Variant Interpretation Working Group. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. *Am. J. Hum. Genet.*, **109**, 2163–2177.
47. Rambla,J., Baudis,M., Ariosa,R., Beck,T., Fromont,L.A., Navarro,A., Paloots,R., Rueda,M., Saunders,G., Singh,B., *et al.* (2022) Beacon v2 and beacon networks: a “lingua franca” for

- federated data discovery in biomedical genomics, and beyond. *Hum. Mutat.*, **43**, 791–799.
48. Freeman,P.J., Hart,R.K., Gretton,L.J., Brookes,A.J. and Dagleish,R. (2018) VariantValidator: accurate validation, mapping, and formatting of sequence variation descriptions. *Hum. Mutat.*, **39**, 61–68.
  49. International Standing Committee on Human Cytogenomic Nomenclature (2020) *ISCN 2020: An International System for Human Cytogenomic Nomenclature*. Karger, p. 2020.
  50. Robinson,J.T., Thorvaldsdottir,H., Turner,D. and Mesirov,J.P. (2023) igv.js: an embeddable JavaScript implementation of the integrative genomics viewer (IGV). *Bioinformatics*, **39**, btac830.
  51. Tavtigian,S.V., Harrison,S.M., Boucher,K.M. and Biesecker,G. (2020) Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. *Hum. Mutat.*, **41**, 1734–1737.
  52. Li,Q. and Wang,K. (2017) InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. *Am. J. Hum. Genet.*, **100**, 267–280.
  53. Fan,C., Wang,Z., Sun,Y., Sun,J., Liu,X., Kang,L., Xu,Y., Yang,M., Dai,W., Song,L., *et al.* (2021) AutoCNV: a semiautomatic CNV interpretation system based on the 2019 ACMG/ClinGen technical standards for CNVs. *Bmc Genomics [Electronic Resource]*, **22**, 721.
  54. Xiang,J., Peng,J., Baxter,S. and Peng,Z. (2020) AutoPVS1: an automatic classification tool for PVS1 interpretation of null variants. *Hum. Mutat.*, **41**, 1488–1498.
  55. Haak,L.L., Fenner,M., Paglione,L., Pentz,E. and Ratner,H. (2012) ORCID: a system to uniquely identify researchers. *Learn. Publ.*, **25**, 259–264.
  56. Crosswell,L.C. and Thornton,J.M. (2012) ELIXIR: a distributed infrastructure for european biological data. *Trends Biotechnol.*, **30**, 241–242.
  57. Rentzsch,P., Witten,D., Cooper,G.M., Shendure,J. and Kircher,M. (2019) CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.*, **47**, D886–D894.
  58. Jaganathan,K., Panagiotopoulou,S.K., McRae,J.F., Darbandi,S.F., Knowles,D., Li,Y.I., Kosmicki,J.A., Arbelaez,J., Cui,W., Schwartz,G.B., *et al.* (2019) Predicting splicing from primary sequence with deep learning. *Cell*, **176**, 535–548.
  59. Ioannidis,N.M., Rothstein,J.H., Pejaver,V., Middha,S., McDonnell,S.K., Baheti,S., Musolf,A., Li,Q., Holzinger,E., Karyadi,D., *et al.* (2016) REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. *Am. J. Hum. Genet.*, **99**, 877–885.
  60. Vasilevsky,N., Essaid,S., Matentzoglou,N., Harris,N.L., Haendel,M., Robinson,P. and Mungall,J. (2020) Mondo disease ontology: harmonizing disease concepts across the world. In: *CEUR Workshop Proceedings, CEUR-WS.Vol. 2807*.